These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Multicenter clinical, double blind, and randomized study to assess the effectiveness and safety of binifibrate versus gemfibrozil in type IIa, IIb, and IV hyperlipidemia].
    Author: Corominas Vilardell A, de Oya Otero M, Escobar Jiménez F, Anguera Vila A, Ariño Armengol B.
    Journal: An Med Interna; 1993 Nov; 10(11):537-41. PubMed ID: 8117868.
    Abstract:
    A multicentric, double-blind and randomized clinical study was conducted on a total of 54 patients with hyperlipidemias type IIa, IIb and IV in order to compare the effectivity and tolerance of two hyperlipemiant drugs: Binifibrate and Gemfibrozil. The treatment had a length of six months, performing clinical and analytical controls at: baseline, 1 month, 2 months, 4 months and 6 months. Both drugs showed a very good tolerance and the following results were obtained: Total cholesterol: Binifibrate -21.9%, Gemfibrozil -20.5%; Triglycerides: Binifibrate -48.6%, Gemfibrozil -43.27%; HDL: Binifibrate +18.2%, Gemfibrozil -12.8%; LDL: Binifibrate -24.3%, Gemfibrozil -22.8% VLDL: Binifibrate -48%, Gemfibrozil -43.2%; Apo A: Binifibrate +133.5%, Gemfibrozil +108.1%; Apo B: Binifibrate -59.7%, Gemfibrozil -46%. Both treatment were very effective, although the greater increase produced by Binifibrate on Chol-HDL, with a statistically significant difference versus the increase produced by Gemfibrozil, must be highlighted.
    [Abstract] [Full Text] [Related] [New Search]